Endo International PLC (ENDP) PT Set at $9.00 by Cantor Fitzgerald
Several other research firms have also recently commented on ENDP. Goldman Sachs Group, Inc. (The) started coverage on Endo International PLC in a research note on Thursday, September 28th. They issued a sell rating and a $7.00 price target on the stock. Piper Jaffray Companies reiterated a hold rating and issued a $9.00 price target on shares of Endo International PLC in a research note on Sunday, September 17th. Mizuho reiterated a buy rating and issued a $14.00 price target (down previously from $19.00) on shares of Endo International PLC in a research note on Tuesday, September 12th. Oppenheimer Holdings, Inc. reiterated a hold rating on shares of Endo International PLC in a research note on Tuesday, August 8th. Finally, Deutsche Bank AG cut their price target on Endo International PLC from $18.00 to $15.00 and set a buy rating on the stock in a research note on Friday, July 7th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $12.64.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The business had revenue of $875.73 million for the quarter, compared to analysts’ expectations of $832.66 million. During the same quarter in the previous year, the firm posted $0.86 earnings per share. The company’s revenue was down 4.9% compared to the same quarter last year.
COPYRIGHT VIOLATION NOTICE: “Endo International PLC (ENDP) PT Set at $9.00 by Cantor Fitzgerald” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/endo-international-plc-endp-pt-set-at-9-00-by-cantor-fitzgerald/1676068.html.
In other Endo International PLC news, COO Terrance J. Coughlin acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was acquired at an average cost of $7.70 per share, with a total value of $154,000.00. Following the acquisition, the chief operating officer now directly owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Blaise Coleman acquired 6,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The stock was acquired at an average cost of $7.89 per share, with a total value of $51,285.00. Following the completion of the acquisition, the chief financial officer now directly owns 13,729 shares in the company, valued at $108,321.81. The disclosure for this purchase can be found here. Insiders have bought 36,000 shares of company stock valued at $279,460 over the last ninety days. Corporate insiders own 0.50% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. James Investment Research Inc. bought a new position in Endo International PLC in the 2nd quarter worth approximately $113,000. Blair William & Co. IL bought a new position in Endo International PLC in the 2nd quarter worth approximately $126,000. Point View Wealth Management Inc. grew its holdings in Endo International PLC by 16.6% in the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock worth $149,000 after buying an additional 1,900 shares in the last quarter. Riverhead Capital Management LLC grew its holdings in Endo International PLC by 64.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after buying an additional 5,887 shares in the last quarter. Finally, Bank of Hawaii bought a new position in Endo International PLC in the 2nd quarter worth approximately $180,000. 90.29% of the stock is owned by institutional investors and hedge funds.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.